FMQ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Isoflex EU Approval Expands Addressable MarketEU approval for Isoflex opens access to >55 million planted hectares across cereals, corn, oilseed rape and potato, creating a durable commercial avenue. Regulatory entry into large EU markets materially increases long-term TAM for a differentiated product and supports branded sales growth.
New Active Ingredients MomentumDoubling of new active ingredient sales evidences a functioning R&D-to-market engine, reducing reliance on legacy molecules. Sustained product launches (fluindapyr, Dodhylex, Isoflex) can progressively restore organic growth, margin mix, and defend pricing versus generics over the medium term.
Strategic Minority Investment To Fund DeleveragingA $400M strategic equity stake from Tessenderlo materially accelerates deleveraging, improves covenant headroom and lowers refinancing risk. The investment includes governance alignment and funding explicitly earmarked for debt reduction, strengthening capital structure durability over the next 2–3 years.
Bears Say
Elevated Leverage And Weakened Balance SheetLeverage expansion and eroded equity reduce financial flexibility and increase sensitivity to operating volatility. High gross/net debt levels and rising interest costs constrain reinvestment, raise refinancing risk, and make covenant compliance and execution of strategic plans contingent on successful asset sales or capital raises.
Negative And Inconsistent Cash GenerationRecent negative operating and free cash flow limit the firm's ability to fund R&D, capex and debt service from operations. This forces reliance on disposals, financings and one-time items to bridge gaps, elevating execution risk and making sustainable cash conversion a key medium-term hurdle for restoring balance-sheet health.
Pricing Pressure From Generics And Partner Revenue DeclineStructural pricing weakness and partner revenue erosion (e.g., diamide transitions) reduce predictable cash flows and compress margins. Post-patent transitions and grower shifts to generics create sustained competitive headwinds that require consistent new-product adoption to offset lost partner volumes over multiple seasons.
FMC News
FMQ FAQ
What was FMC Corp’s price range in the past 12 months?
Currently, no data Available
What is FMC Corp’s market cap?
FMC Corp’s market cap is CHF1.14B.
When is FMC Corp’s upcoming earnings report date?
FMC Corp’s upcoming earnings report date is Jul 29, 2026 which is in 22 days.
How were FMC Corp’s earnings last quarter?
FMC Corp released its earnings results on Apr 29, 2026. The company reported -$0.185 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.122.
Is FMC Corp overvalued?
According to Wall Street analysts FMC Corp’s price is currently Undervalued.
Does FMC Corp pay dividends?
FMC Corp does not currently pay dividends.
What is FMC Corp’s EPS estimate?
FMC Corp’s EPS estimate is 0.18.
How many shares outstanding does FMC Corp have?
Currently, no data Available
What happened to FMC Corp’s price movement after its last earnings report?
FMC Corp reported an EPS of -$0.185 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of FMC Corp?
Currently, no hedge funds are holding shares in CH:FMQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
FMC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF12.94 (― Downside)
CHF12.94 (― Downside)
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.55%
12-Months-Change
Fundamentals
Return on Equity
-83.04%
Trailing 12-Months
Asset Growth
-20.18%
Trailing 12-Months
Company Description
FMC Corp
FMC Corporation functions as an agricultural science enterprise, delivering products for crop safeguarding, plant wellness, and professional pest and turf management. The company is responsible for creating, commercializing, and selling various crop protection chemicals, including insecticides, herbicides, and fungicides, alongside biologicals, crop nutrition supplements, and seed treatment solutions. These innovations are employed in farming to boost harvest quantity and quality by mitigating diverse insect infestations, weed growth, and plant ailments. Furthermore, its solutions cater to non-agricultural sectors for general pest control. FMC distributes its comprehensive product range through its proprietary sales teams, in collaboration with alliance partners, and via independent distributors and sales representatives. Established in 1883, FMC Corporation is based in Philadelphia, Pennsylvania, and conducts operations across North America, Latin America, Europe, the Middle East, Africa, and Asia.
FMQ Company Deck
FMQ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company beat Q1 guidance, showed meaningful growth in new active ingredients (sales doubled Y/Y), secured regulatory approval for Isoflex in the EU, and has concrete plans and partial line-of-sight to achieve targeted 2026 debt paydown. However, FMC faces material near-term headwinds including lower partner-related revenues, mid-single-digit to double-digit declines in Q2 and full-year EBITDA and EPS, elevated interest expense and leverage, negative Q1 free cash flow, and ongoing cost/tariff uncertainties. Management expects the first half to be an earnings trough with sequential improvement in H2 and stronger results in 2027, but execution risk remains.View all CH:FMQ earnings summariesFMQ Revenue Breakdown
45.36% Insecticides
35.96% Herbicides
10.46% Fungicides
5.51% Plant Health
2.71% Other
FMQ Stock 12 Month Forecast
Average Price Target
$12.94
Options Prices
Currently, No data available
---